David A. Siegel Recursion Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 489,900 shares of RXRX stock, worth $3.67 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
489,900
Previous 435,800
12.41%
Holding current value
$3.67 Million
Previous $3.27 Million
1.22%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding RXRX
# of Institutions
291Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$245 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$189 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$182 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$130 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$115 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.35B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...